Inhibikase Therapeutics (IKT) Free Cash Flow (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Free Cash Flow data on file, last reported at -$12.1 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 192.93% year-over-year to -$12.1 million in Q1 2026; TTM through Mar 2026 was -$35.7 million, a 84.26% decrease from a year earlier, with the FY2025 full-year figure at -$27.8 million, down 45.18% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$12.1 million, down from -$7.5 million in the prior quarter.
• Over the last five years, Free Cash Flow for IKT reached as high as -$3.4 million in Q4 2023 and fell as low as -$12.1 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$5.6 million across 5 years, with a median of -$4.9 million in 2024.
• Across the five-year window, Free Cash Flow surged 35.25% in 2024 and plunged 192.93% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$3.6 million in 2022, then rose by 3.2% to -$3.4 million in 2023, then plunged by 55.28% to -$5.3 million in 2024, then slumped by 40.6% to -$7.5 million in 2025, then tumbled by 60.45% to -$12.1 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$12.1 million in Q1 2026, -$7.5 million in Q4 2025, and -$10.6 million in Q3 2025.